| Pfizer |
USA FDA:
main webpage
,
Emergency Use Authorisation review memorandum
(57 pages),
EUA review memorandum for 12–15 year olds
(43 pages), advisory committee briefing documents (
FDA
,
Pfizer
)
UK MHRA:
main webpage
,
public assessment report
(51 pages)
AUS TGA:
main webpage
,
public assessment report
(42 pages)
EU EMA:
main webpage
,
public assessment report
(140 pages),
clinical information
(6990 pages)
Canada HC:
main webpage
,
summary basis of decision
(63 pages),
clinical information
(5910 pages)
Japan PMDA: main webpage (
English
,
Japanese
),
public assessment reportok
(74 pages),
clinical and non-clinical information
(1239 pages)
WHO:
main webpage
,
background document to the WHO interim recommendations
(44 pages) |
| Moderna |
USA FDA:
main webpage
,
Emergency Use Authorisation review memorandum
(61 pages), advisory committee meeting briefing documents (
FDA
,
Moderna
)
UK MHRA:
main webpage
,
public assessment report
(7 pages)
EU EMA:
main webpage
,
public assessment report
(169 pages),
clinical information
(6095 pages)
Canada HC:
main webpage
,
summary basis of decision (61 pages),
clinical information
(6095 pages)
Japan PMDA: main webpage (
English
,
Japanese
),
public assessment report
(74 pages),
clinical and non-clinical information
(542 pages)
WHO:
main webpage
,
background document to the WHO interim recommendations
(41 pages) |
| Oxford/AZ |
UK MHRA:
main webpage
,
public assessment report
(58 pages)
AUS TGA:
main webpage
,
public assessment report
(49 pages)
EU EMA:
main webpage
,
public assessment report
(181 pages)
Canada HC:
main webpage
,
summary basis of decision
(66 pages)
Japan PMDA: main webpage (
English
,
Japanese
),
public assessment report
(122 pages),
clinical and non-clinical information
(1134 pages)
WHO:
main webpage
,
background document to the WHO interim recommendations
(56 pages) |
| Janssen |
USA FDA:
main webpage
,
Emergency Use Authorisation review memorandum
(69 pages), advisory committee meeting briefing documents (
FDA
,
Janssen
)
UK MHRA:
main webpage
,
public assessment report
(11 pages)
EU EMA:
main webpage
,
public assessment report
(218 pages)
Canada HC:
main webpage
,
summary basis of decision
(60 pages)
WHO:
main webpage
,
background document to the WHO interim recommendations
(54 pages) |
| Novavax | None |
| Gamaleya Research Institute | None |
| Sinopharm |
WHO:
main webpage
,
background document to the WHO interim recommendations
(23 pages) |
| Sinovac |
WHO:
main webpage
,
background document to the WHO interim recommendations
(30 pages) |